Molecular Partners AG
c/o Department of Biochemistry
Winterthurerstrasse 190
Zürich
8057
Tel: 41-44-635-65-00
Fax: 41-44-635-65-07
Website: http://www.molecularpartners.com/
Email: info@molecularpartners.com
81 articles with Molecular Partners AG
-
All development and commercialization rights for MP0310, a clinical stage immunomodulator intended to treat solid tumors, will be reverted to Molecular Partners.
-
The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.
-
Clinical Catch-Up: January 10-14
1/17/2022
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look. -
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
-
The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
-
AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here's more about it.
-
Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
6/15/2021
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million.
-
Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
6/13/2021
Molecular Partners AG announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership designed to speed development of treatments and vaccine candidates for COVID-19.
-
Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States
6/9/2021
Molecular Partners AG today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares.
-
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
5/27/2021
EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization
-
Molecular Partners' COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro
5/6/2021
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced results from parallel laboratory studies conducted in collaboration with academic and government partners in Switzerland and the United States.
-
Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline
5/4/2021
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced its interim management statement for the period ending March 31, 2021.
-
2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...
4/27/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021. -
Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
4/23/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing common shares, in the United States.
-
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company's work in the development of protein-based treatments for COVID-19 and various cancers.
-
Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli Elected New Board Members
4/21/2021
At todays AGM of Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority.
-
Clinical Catch-Up: April 5-9
4/12/2021
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more. -
Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
4/10/2021
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research virtual Annual Meeting.